Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells

References

• Fang Y, Yu H, Liang X, Xu J, Cai X. Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. Cancer Biol Ther 2014; 15:1268-79; PMID:24971465; http://dx.doi.org/10.4161/cbt.29691
   PubMed Web of Science ®Google Scholar
• Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, Ma BB, Mak TW, Ng SS, To KF. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther 2014; 15:768-76; PMID:24642870; http://dx.doi.org/10.4161/cbt.28550
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 2012; 13:e362-9; PMID:22846841; http://dx.doi.org/10.1016/S1470-2045(12)70210-3
   PubMed Web of Science ®Google Scholar
• Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011; 12:239-51; PMID:21725213; http://dx.doi.org/10.4161/cbt.12.3.17034
   PubMed Web of Science ®Google Scholar
• Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol 2014; 27:9-14; PMID:24714764
   PubMedGoogle Scholar
• Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23:634-46; PMID:23680148; http://dx.doi.org/10.1016/j.ccr.2013.03.022
   PubMed Web of Science ®Google Scholar
• Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012; 14:207-14; PMID:23021375
   PubMed Web of Science ®Google Scholar
• Bottini C, Platini F, Rinaldi M, Leutner M, Alabiso O, Garavoglia M, Tessitore L. p27Kip1 is inactivated in human colorectal cancer by cytoplasmic localization associated with activation of Akt/PKB. Int J Oncol 2009; 34:69-77; PMID:19082479
   PubMed Web of Science ®Google Scholar
• Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer 2002; 95:2479-86; PMID:12467060; http://dx.doi.org/10.1002/cncr.10986
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012; 3:137-51; PMID:22773955
   PubMedGoogle Scholar
• Mor A, White MA, Fontoura BM. Nuclear trafficking in health and disease. Curr Opin Cell Biol 2014; 28:28-35; PMID:24530809; http://dx.doi.org/10.1016/j.ceb.2014.01.007
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, Xi Q, Liu R, Di W. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett 2014; 343:6-13; PMID:24018641; http://dx.doi.org/10.1016/j.canlet.2013.09.002
   PubMed Web of Science ®Google Scholar
• Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65:153-9; discussion 9–60; PMID:19574837; http://dx.doi.org/10.1227/01.NEU.0000348550.47441.4B
   PubMed Web of Science ®Google Scholar
• Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013; 41:67-78 e4; PMID:22986101; http://dx.doi.org/10.1016/j.exphem.2012.09.002
   PubMed Web of Science ®Google Scholar
• Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 2014; 4:527-37; PMID:24743138; http://dx.doi.org/10.1158/2159-8290.CD-13-1005
   PubMed Web of Science ®Google Scholar
• Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)–a novel class of anti-cancer agents. J Hematol Oncol 2014; 7:78; PMID:25316614; http://dx.doi.org/10.1186/s13045-014-0078-0
   PubMed Web of Science ®Google Scholar
• Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X, Yu R, Xu K. CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin. J Pharmacol Sci 2014; 124:486-93; PMID:24739265; http://dx.doi.org/10.1254/jphs.13240FP
   PubMed Web of Science ®Google Scholar
• Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83:1021-32; PMID:22209898; http://dx.doi.org/10.1016/j.bcp.2011.12.016
   PubMed Web of Science ®Google Scholar
• Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74:648-9; PMID:8761384; http://dx.doi.org/10.1038/bjc.1996.415
   PubMed Web of Science ®Google Scholar
• Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 2014; 27:74-86; PMID:24755012; http://dx.doi.org/10.1016/j.semcancer.2014.04.005
   PubMed Web of Science ®Google Scholar
• Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol 2014; 27:62-73; PMID:24631834; http://dx.doi.org/10.1016/j.semcancer.2014.03.001
   PubMed Web of Science ®Google Scholar
• Mau-Soerensen M, Razak ARA, Mahipal A, Mahaseth H, Gerecitano JF, Shacham S, Yau CYF, Lassen U, Shields AF, McCauley D, et al. Safety and antitumor activity of selinexor (KPT-330), a first-in -class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. J Clin Oncol 2014; 32:482; abstract; PMID:24395844; http://dx.doi.org/10.1200/JCO.2013.53.3448
   PubMed Web of Science ®Google Scholar
• Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 118:3922-31; PMID:21841164; http://dx.doi.org/10.1182/blood-2011-01-333138
   PubMed Web of Science ®Google Scholar
• Hilliard M, Frohnert C, Spillner C, Marcone S, Nath A, Lampe T, Fitzgerald DJ, Kehlenbach RH. The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export. J Biol Chem 2010; 285:22202-10; PMID:20457605; http://dx.doi.org/10.1074/jbc.M110.131821
   PubMed Web of Science ®Google Scholar
• Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 2013; 110:1303-8; PMID:23297231; http://dx.doi.org/10.1073/pnas.1217203110
   PubMed Web of Science ®Google Scholar
• Ewing I, Hurley JJ, Josephides E, Millar A. The molecular genetics of colorectal cancer. Frontline Gastroenterol 2014; 5:26-30; PMID:24416503; http://dx.doi.org/10.1136/flgastro-2013-100329
   PubMedGoogle Scholar
• Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003; 4:463-76; PMID:14706338; http://dx.doi.org/10.1016/S1535-6108(03)00303-9
   PubMed Web of Science ®Google Scholar
• Jirawatnotai S, Sharma S, Michowski W, Suktitipat B, Geng Y, Quackenbush J, Elias JE, Gygi SP, Wang YE, Sicinski P. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis. Cell Cycle 2014; 13:2889-900; PMID:25486477; http://dx.doi.org/10.4161/15384101.2014.946850
   PubMed Web of Science ®Google Scholar
• Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget 2014; 5:6102-12; PMID:25026284
   PubMedGoogle Scholar
• Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme AM. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002; 99:14440-5; PMID:12374846; http://dx.doi.org/10.1073/pnas.212285299
   PubMed Web of Science ®Google Scholar
• Niu M, Sun Y, Liu X, Tang L, Qiu R. Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells. J Pharmacol Sci 2013; 121:17-24; PMID:23269238; http://dx.doi.org/10.1254/jphs.12206FP
   PubMed Web of Science ®Google Scholar
• Liu X, Cai W, Niu M, Chong Y, Liu H, Hu W, Wang D, Gao S, Shi Q, Hu J, et al. Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1. J Neurooncol 2015; 121:469-77; PMID:25528634; http://dx.doi.org/10.1007/s11060-014-1664-2
   PubMed Web of Science ®Google Scholar